Literature DB >> 20105405

Ocular surface effects of thyroid disease.

Jason A Sokol1, Gary N Foulks, Ali Haider, William R Nunery.   

Abstract

The orbital manifestations of ophthalmic Graves' disease have been appreciated since the first description of the disease many years ago. The effects of ophthalmic Graves' disease on the ocular surface, although some of the most bothersome and potentially damaging features of the disease, are often not as well appreciated. This review identifies and summarizes the manifestations of ocular surface disease attendant to ophthalmic Graves' disease and provides recommendations for clinical evaluation and management options to control the ocular surface problems.

Entities:  

Mesh:

Year:  2010        PMID: 20105405     DOI: 10.1016/s1542-0124(12)70215-x

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  5 in total

1.  Therapeutic use of mini-scleral lenses in a patient with Graves' ophthalmopathy.

Authors:  Jennifer S Harthan
Journal:  J Optom       Date:  2013-01-09

Review 2.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

Review 3.  The relationship between Graves' ophthalmopathy and dry eye syndrome.

Authors:  Jessica H Selter; Anisa I Gire; Shameema Sikder
Journal:  Clin Ophthalmol       Date:  2014-12-31

4.  In vivo confocal microscopy assessment of meibomian glands microstructure in patients with Graves' orbitopathy.

Authors:  Shengnan Cheng; Yueqi Yu; Jin Chen; Lin Ye; Xinghua Wang; Fagang Jiang
Journal:  BMC Ophthalmol       Date:  2021-06-19       Impact factor: 2.209

5.  The function and morphology of Meibomian glands in patients with thyroid eye disease: a preliminary study.

Authors:  Chia-Yu Wang; Ren-Wen Ho; Po-Chiung Fang; Hun-Ju Yu; Chun-Chih Chien; Chang-Chun Hsiao; Ming-Tse Kuo
Journal:  BMC Ophthalmol       Date:  2018-04-12       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.